AŁ
Therapeutic Areas
Captor Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CT-03 | Chemotherapy-resistant Acute Myeloid Leukaemia (AML) and other liquid/solid tumors | Preclinical / Phase I Prep |
| Undisclosed Immune-Stimulating Degrader | Colorectal Cancer | Preclinical |
| Undisclosed Degrader Program | Rheumatoid Arthritis / Inflammatory Bowel Disease | Discovery |
Leadership Team at Captor Therapeutics
MW
Michał Walczak
Chief Executive Officer, Chief Scientific Officer
AP
Anna Pawluk
Chief Operating Officer